Platelet Transfusion Refractoriness

Platelet Transfusion Refractoriness Clinical Trial

— ACERTP  

Official title:

Characterization of Anti-HLA I Antibodies Involved in Platelet Transfusion Refractoriness: Optimization of the Transfusion Management of Patients With Severe Thrombocytopenia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05399693
• Other study ID #: 2021-006
• Status: Recruiting
• Start date: February 2, 2022
• Est. completion date: November 2, 2023

Study information

• Verified date: September 2023
• Source: Institut de cancérologie Strasbourg Europe
• Contact: Manon VOEGELIN
• Phone: 03 68 33 95 23
• Email: promotion-rc[@]icans.eu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Platelet Transfusion Refractoriness is one of the severe complications after multiple transfusions in patients with severe thrombopenia. Platelet Transfusion Refractoriness is characterized by inefficient transfusion and arise from allo-antibodies specific of platelets antigenes, mostly carried by HLA-I molecules.

Description:

A preliminary study has shown different isotypes of anti-HLA I in patients with Platelet Transfusion Refractoriness. Our hypothesis is that the type of anti-HLA I antibodies (recognised epitope, quantity, isotype) should establish predictive and diagnostic criteria for Platelet Transfusion Refractoriness.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: November 2, 2023
• Est. primary completion date: November 2, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patient with Hematopoietic stem cells graft (autograft or allograft) or with acute leukemia with the indication of platelet transfusion.

Exclusion Criteria:

• Patient under guardianship

• Minor patient

Related Conditions & MeSH terms

• Platelet Transfusion Refractoriness

Intervention

Procedure:
• platelet transfusion
platelet transfusion realised for Hematopoietic stem cells graft or for acute leukemia

Locations

Country	Name	City	State
France	Institut de cancérologie Strasbourg Europe	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
Institut de cancérologie Strasbourg Europe

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Research of predictive criteria of Platelet transfusion refractoriness	Characterisation of anti-HLA I antibodies (recognised epitopes and isotypes) associated to Platelet transfusion refractoriness	blood samples before the transfusion of each chemotherapy cycle